Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $4.14 on Friday. The stock’s 50-day simple moving average is $3.38 and its 200-day simple moving average is $3.90. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, equities analysts predict that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.